339 related articles for article (PubMed ID: 28651743)
1. The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells.
Ye JF; Qi WX; Liu MY; Li Y
Cell Immunol; 2017 Aug; 318():35-41. PubMed ID: 28651743
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
[TBL] [Abstract][Full Text] [Related]
3. CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells.
Li Y; Li YF; Si CZ; Zhu YH; Jin Y; Zhu TT; Liu MY; Liu GY
Virus Res; 2016 Jul; 220():172-8. PubMed ID: 27157859
[TBL] [Abstract][Full Text] [Related]
4. Enhanced growth suppression of TERT-positive tumor cells by oncolytic adenovirus armed with CCL20 and CD40L.
Liu GY; Li ZJ; Li QL; Jin Y; Zhu YH; Wang YH; Liu MY; Li YG; Li Y
Int Immunopharmacol; 2015 Sep; 28(1):487-93. PubMed ID: 26208317
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated CCL20/IL-15 gene transfer enhances antitumor immunity in mice.
Liu GY; Jia QY; Li ZJ; Li YG; Zhang MM; Liu MY; Wang XL; Li Y
Immunobiology; 2014 Jun; 219(6):475-81. PubMed ID: 24657179
[TBL] [Abstract][Full Text] [Related]
6. Hydrogel-based co-delivery of CIK cells and oncolytic adenovirus armed with IL12 and IL15 for cancer immunotherapy.
Du YN; Wei Q; Zhao LJ; Fan CQ; Guo LR; Ye JF; Li Y
Biomed Pharmacother; 2022 Jul; 151():113110. PubMed ID: 35605298
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity.
Yan Y; Li S; Jia T; Du X; Xu Y; Zhao Y; Li L; Liang K; Liang W; Sun H; Li R
Tumour Biol; 2015 Jun; 36(6):4535-43. PubMed ID: 25627006
[TBL] [Abstract][Full Text] [Related]
8. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
[TBL] [Abstract][Full Text] [Related]
9. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma.
Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J
Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525
[TBL] [Abstract][Full Text] [Related]
10. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
11. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
Chen D; Huang L; Zhou H; Zhang Y
Front Immunol; 2021; 12():615089. PubMed ID: 33717103
[TBL] [Abstract][Full Text] [Related]
12. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
13. Antitumor Effects of Oncolytic Adenovirus-Carrying siRNA Targeting Potential Oncogene EphA3.
Zhao Y; Li H; Wu R; Li S; Wang P; Wang H; Wang J; Zhou J
PLoS One; 2015; 10(5):e0126726. PubMed ID: 25978371
[TBL] [Abstract][Full Text] [Related]
14. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.
Lapteva N; Aldrich M; Weksberg D; Rollins L; Goltsova T; Chen SY; Huang XF
J Immunother; 2009; 32(2):145-56. PubMed ID: 19238013
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
16. Telomerase-dependent oncolytic adenovirus for cancer treatment.
Huang TG; Savontaus MJ; Shinozaki K; Sauter BV; Woo SL
Gene Ther; 2003 Aug; 10(15):1241-7. PubMed ID: 12858189
[TBL] [Abstract][Full Text] [Related]
17. Interleukin‑15: a potent adjuvant enhancing the efficacy of an autologous whole‑cell tumor vaccine against Lewis lung carcinoma.
Chen X; Ni J; Meng H; Li D; Wei Y; Luo Y; Wu Y
Mol Med Rep; 2014 Oct; 10(4):1828-34. PubMed ID: 25109355
[TBL] [Abstract][Full Text] [Related]
18. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
19. hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.
Jiang W; Zhang C; Tian Z; Zhang J
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1279-1288. PubMed ID: 29737430
[TBL] [Abstract][Full Text] [Related]
20. Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine.
Wang Y; Zhang J; Wu Y; Ding ZY; Luo XM; Liu J; Zhong WN; Deng GH; Xia XY; Deng YT; Wei YQ; Jiang Y
Sci Rep; 2015 Jun; 5():11275. PubMed ID: 26085010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]